Comparative Pharmacology
Head-to-head clinical analysis: HYTRIN versus SILODOSIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYTRIN versus SILODOSIN.
HYTRIN vs SILODOSIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).
Silodosin is a highly selective antagonist of alpha-1A adrenergic receptors located primarily in the prostate, bladder base, and proximal urethra. Blockade of these receptors relaxes smooth muscle in these tissues, reducing urinary outflow resistance and improving symptoms of benign prostatic hyperplasia (BPH). It has minimal affinity for alpha-1B receptors, thereby reducing the risk of orthostatic hypotension compared to non-selective alpha blockers.
Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.
8 mg orally once daily with a meal.
None Documented
None Documented
Clinical Note
moderateSilodosin + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Tranilast
"Silodosin may increase the hypotensive activities of Tranilast."
Clinical Note
moderateSilodosin + Prednisone
Terminal elimination half-life: 12–13 hours (range 10–15 h); clinical context: steady state achieved in 2–3 days; dose adjustment not required in renal impairment but caution in hepatic impairment.
Terminal half-life: 11-13 hours; allows once-daily dosing; prolongation in severe renal impairment
Renal: ~40% as metabolites, <1% unchanged; biliary/fecal: ~60% as metabolites; total clearance 6.4 L/h.
Renal (33.5% as unchanged drug, 64.3% as metabolites); fecal (<5%)
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker
"The serum concentration of Prednisone can be increased when it is combined with Silodosin."